Have a personal or library account? Click to login
Mechanistic study of novel arylpiperazine derivative NAF19 in prostate cancer treatment based on network pharmacology approach Cover

Mechanistic study of novel arylpiperazine derivative NAF19 in prostate cancer treatment based on network pharmacology approach

Revista Romana de Medicina de Laborator
Volume 34 (2026): Issue 1 (January 2026)
By: Hua Jiang,  Mingzhen Xu,  Songsong Jiang,  Weiqiang Huang and  Hong Chen  
Open Access
|Feb 2026

Authors

Hua Jiang

jianghua426@zmu.edu.cn

Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical University, China

Mingzhen Xu

Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical University, China

Songsong Jiang

Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical University, China

Weiqiang Huang

The Department of Biological and Pharmaceutical Sciences, Zhuhai Campus of Zunyi Medical University, China

Hong Chen

Luoyang Key Laboratory of Organic Functional Molecules, College of Food and Drug, Luoyang Normal University, China
DOI: https://doi.org/10.2478/rrlm-2026-0001 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 27 - 38
Submitted on: Aug 21, 2025
|
Accepted on: Nov 12, 2025
|
Published on: Feb 5, 2026
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
arylpiperazine derivative,
CXCR4,
network pharmacology,
prostate cancer
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2026 Hua Jiang, Mingzhen Xu, Songsong Jiang, Weiqiang Huang, Hong Chen, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 34 (2026): Issue 1 (January 2026)Next article